Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes

• DOI: 10.1016/j.jad.2021.03.073
• Publication Date: 2021-04-01T08:50:05Z
• Authors: K. Heerlein; G. Perugi; C. Otte; T. Frodl; G. Degraeve; W. Hagedoorn; A.J. Oliveira-Maia; V. Perez Sola; S. Rathod; G. Rosso; P. Sierra; S. Malynn; J. Morrens; C. Verrijcken; B. Gonzalez; A.H. Young
• Keywords: Depression; Treatment-Resistant Depression; Real world evidence

Treatment resistant depression (TRD) characterizes a subgroup of 10-30% patients with major depressive disorder, and is associated considerable morbidity mortality. A consensus treatment for TRD does not exist, which often leads to wide variations in strategies. Real-world studies on patterns outcomes Europe are lacking could help elucidate current strategies their efficacy.This non-interventional cohort study (defined as failure ≥2 oral antidepressants given at adequate dose duration) moderate severe collected real-world data several European countries. Patients were started new according routine clinical practice.Among 411 enrolled, after 6 months, only 16.7% achieved remission 73.5% showed no response. At Month 12, while 19.2% 69.2% response, 33.3% those longer remission. Pharmacological treatments employed heterogenous; 54 different drugs recorded baseline, the top 5 types drug classes accounted 40.0% patients. Even though rates very low, 60.0% had changed since enrolment.The heterogeneity highlights lack consensus. Moreover, despite low response rates, remained substantial periods time. These further support existence an unmet need Europe.